

# Patrick F Smith

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5268818/publications.pdf>

Version: 2024-02-01

98  
papers

3,591  
citations

136950

32  
h-index

149698

56  
g-index

101  
all docs

101  
docs citations

101  
times ranked

3997  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168). <i>Clinical and Translational Science</i> , 2022, 15, 442-450.	3.1	21
2	Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment. <i>Journal of Clinical Lipidology</i> , 2022, 16, 208-219.	1.5	32
3	A thorough <scp>QTc</scp> study to evaluate the effects of oral rilzabrutinib administered alone and with ritonavir in healthy subjects. <i>Clinical and Translational Science</i> , 2022, , .	3.1	2
4	Dosing will be a key success factor in repurposing antivirals for COVID-19. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3451-3454.	2.4	34
5	Pharmacologic effects of oseltamivir in immunocompromised adult patients as assessed by population PK/PD analysis and drug-disease modelling for dosing regimen optimization. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1359-1368.	2.4	4
6	Using in silico viral kinetic models to guide therapeutic strategies during a pandemic: An example in SARS-CoV-2. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3425-3438.	2.4	5
7	Model-Informed Drug Development for Anti-Infectives: State of the Art and Future. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 867-891.	4.7	41
8	Blueprint for pandemic response: Focus on translational medicine, clinical pharmacology and pharmacometrics. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3398-3407.	2.4	1
9	Timing of Antiviral Treatment Initiation is Critical to Reduce SARS-CoV-2 Viral Load. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 509-514.	2.5	170
10	Clinical and virological responses to a broad-spectrum human monoclonal antibody in an influenza virus challenge study. <i>Antiviral Research</i> , 2020, 184, 104763.	4.1	13
11	Optimizing COVID-19 Candidate Therapeutics: Thinking Without Borders. <i>Clinical and Translational Science</i> , 2020, 13, 830-834.	3.1	10
12	Accelerating Clinical Evaluation of Repurposed Combination Therapies for COVID-19. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 1364-1366.	1.4	23
13	Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study. <i>EBioMedicine</i> , 2019, 40, 574-582.	6.1	60
14	Respiratory syncytial virus-A dynamics and the effects of lumicitabine, a nucleoside viral replication inhibitor, in experimentally infected humans. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 442-452.	3.0	20
15	A Pharmacokinetic/Viral Kinetic Model to Evaluate Treatment of Chronic HCV Infection with a Non-Nucleoside Polymerase Inhibitor. <i>Antiviral Therapy</i> , 2018, 23, 353-361.	1.0	3
16	Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemics. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1580-1594.	2.4	36
17	A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2367-2376.	2.4	79
18	Applications of Influenza Viral Kinetic Modeling in Drug Development. <i>Current Pharmacology Reports</i> , 2017, 3, 294-300.	3.0	3

#	ARTICLE	IF	CITATIONS
19	Modelling the Interaction between Danoprevir and Mericitabine in the Treatment of Chronic HCV Infection. <i>Antiviral Therapy</i> , 2016, 21, 297-306.	1.0	2
20	Safety and Upper Respiratory Pharmacokinetics of the Hemagglutinin Stalk-Binding Antibody VIS410 Support Treatment and Prophylaxis Based on Population Modeling of Seasonal Influenza A Outbreaks. <i>EBioMedicine</i> , 2016, 5, 147-155.	6.1	48
21	A Pharmacokinetic/Viral Kinetic Model to Evaluate the Treatment Effectiveness of Danoprevir against Chronic HCV. <i>Antiviral Therapy</i> , 2015, 20, 469-477.	1.0	7
22	Characterization of the Transmembrane Transport and Absolute Bioavailability of the HCV Protease Inhibitor Danoprevir. <i>Clinical Pharmacokinetics</i> , 2015, 54, 537-549.	3.5	10
23	A Drug-Disease Model Describing the Effect of Oseltamivir Neuraminidase Inhibition on Influenza Virus Progression. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5388-5395.	3.2	23
24	Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study. <i>New England Journal of Medicine</i> , 2015, 373, 2048-2058.	27.0	183
25	Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naïve <sc>HCV</sc> genotype 1 patients: <sc>INFORM</sc>-<sc>SVR</sc> study. <i>Liver International</i> , 2015, 35, 79-89.	3.9	21
26	Efficacy and Safety of Danoprevir-Ritonavir plus Peginterferon Alfa-2a+Ribavirin in Hepatitis C Virus Genotype 1 Prior Null Responders. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1136-1145.	3.2	19
27	Comparative benefit of malaria chemoprophylaxis modelled in United Kingdom travellers. <i>Travel Medicine and Infectious Disease</i> , 2014, 12, 726-732.	3.0	6
28	Evaluation of the effect of mericitabine at projected therapeutic and suprathreshold doses on cardiac repolarization in healthy subjects: A thorough QT/QTc study. <i>Clinical Pharmacology in Drug Development</i> , 2014, 3, 179-186.	1.6	1
29	Understanding the effect of the <sc>HCV</sc> polymerase inhibitor mericitabine on early viral kinetics in the phase 2 <sc>JUMP</sc>-<sc>C</sc> and <sc>PROPEL</sc> studies. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 533-542.	2.4	2
30	Effect of Ritonavir-Boosted Danoprevir, a Potent Hepatitis <sc>C</sc> Virus Protease Inhibitor, on the Pharmacokinetics of Methadone in Healthy Subjects Undergoing Methadone Maintenance Therapy. <i>Pharmacotherapy</i> , 2014, 34, 220-226.	2.6	3
31	Pharmacokinetics and Pharmacodynamics of Setrobuvir, an Orally Administered Hepatitis C Virus Non-Nucleoside Analogue Inhibitor. <i>Clinical Therapeutics</i> , 2014, 36, 2047-2063.e3.	2.5	10
32	The Effect of Mild to Moderate Renal Impairment on the Pharmacokinetics of the Nucleoside Analog Hepatitis C Virus Polymerase Inhibitor Mericitabine. <i>Drug Development Research</i> , 2014, 75, 107-113.	2.9	1
33	Two-way interaction study between ritonavir-boosted danoprevir, a potent HCV protease inhibitor, and ketoconazole in healthy subjects. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2014, 52, 103-111.	0.6	3
34	Influence of chronic hepatitis C infection on cytochrome P450 3a4 activity using midazolam as an in vivo probe substrate. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1777-1784.	1.9	40
35	A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1939-1949.	1.9	23
36	Clinical Pharmacology Knowledge, Opportunities and Working Strengths (<sc>CPKNOWS</sc>): a competency model for pursuit of excellence in clinical pharmacology. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 841-845.	2.4	2

#	ARTICLE	IF	CITATIONS
37	Hepatitis C Viral Kinetics. <i>Clinics in Liver Disease</i> , 2013, 17, 13-26.	2.1	25
38	Pharmacokinetics of a Three-Way Drug Interaction Between Danoprevir, Ritonavir and the Organic Anion Transporting Polypeptide (OATP) Inhibitor Ciclosporin. <i>Clinical Pharmacokinetics</i> , 2013, 52, 805-813.	3.5	16
39	Pharmacokinetic-Pharmacodynamic Determinants of Oseltamivir Efficacy Using Data from Phase 2 Inoculation Studies. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3478-3487.	3.2	26
40	Effect of Ritonavir-Boosted Danoprevir, a Potent Hepatitis C Virus Protease Inhibitor, on QTc Interval in Healthy Subjects: Results from a Thorough Study. <i>Drug Development Research</i> , 2013, 74, 306-315.	2.9	1
41	Effect of meal and antisecretory agents on the pharmacokinetics of danoprevir/ritonavir in healthy volunteers. <i>Journal of Pharmacy and Pharmacology</i> , 2013, 66, 23-31.	2.4	9
42	Population Pharmacokinetics of Oseltamivir: Pediatrics through Geriatrics. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3470-3477.	3.2	20
43	Analysis of Hepatitis C Virus Decline during Treatment with the Protease Inhibitor Danoprevir Using a Multiscale Model. <i>PLoS Computational Biology</i> , 2013, 9, e1002959.	3.2	83
44	Virologic Escape during Danoprevir (ITMN-191/RG7227) Monotherapy Is Hepatitis C Virus Subtype Dependent and Associated with R155K Substitution. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 271-279.	3.2	37
45	Pharmacokinetic/Pharmacodynamic Predictors of Clinical Potency for Hepatitis C Virus Nonnucleoside Polymerase and Protease Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3144-3156.	3.2	41
46	Impact of Low-Dose Ritonavir on Danoprevir Pharmacokinetics. <i>Clinical Pharmacokinetics</i> , 2012, 51, 457-465.	3.5	19
47	Effect of IL28B Genotype on Early Viral Kinetics During Interferon-Free Treatment of Patients With Chronic Hepatitis C. <i>Gastroenterology</i> , 2012, 142, 790-795.	1.3	91
48	Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128). <i>Hepatology</i> , 2012, 55, 1030-1037.	7.3	51
49	Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: A phase 1b multiple ascending dose study. <i>Journal of Hepatology</i> , 2011, 54, 1130-1136.	3.7	57
50	Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN $\alpha$ -2a/RBV in hepatitis C patients. <i>Journal of Hepatology</i> , 2011, 55, 972-979.	3.7	48
51	Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible. <i>Biopharmaceutics and Drug Disposition</i> , 2011, 32, 261-275.	1.9	20
52	Danoprevir Monotherapy Decreases Inflammatory Markers in Patients with Chronic Hepatitis C Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3125-3132.	3.2	12
53	Antiviral Activity of Danoprevir (ITMN-191/RG7227) in Combination With Pegylated Interferon $\alpha$ -2a and Ribavirin in Patients With Hepatitis C. <i>Journal of Infectious Diseases</i> , 2011, 204, 601-608.	4.0	19
54	Beyond Genetics: Stratified and Personalised Medicines Using Multiple Parameters. <i>Pharmaceuticals</i> , 2010, 3, 1637-1651.	3.8	4

#	ARTICLE	IF	CITATIONS
55	Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. <i>Lancet</i> , The, 2010, 376, 1467-1475.	13.7	313
56	Effect of saquinavir/ritonavir (1000/100mg bid) on the pharmacokinetics of methadone in opiate-dependent HIV-negative patients on stable methadone maintenance therapy. <i>Addiction Biology</i> , 2009, 14, 321-327.	2.6	16
57	Capecitabine, Oxaliplatin and Radiotherapy: A Phase IB Neoadjuvant Study for Esophageal Cancer with Gene Expression Analysis. <i>Cancer Investigation</i> , 2009, 27, 193-200.	1.3	14
58	A Phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 499-508.	2.3	31
59	A grapefruit a day for patients infected with hepatitis C?. <i>Hepatology</i> , 2008, 47, 2141-2142.	7.3	1
60	Pharmacokinetics and Pharmacodynamics of Methadone Enantiomers After Coadministration with Fosamprenavir-Ritonavir in Opioid-Dependent Subjects. <i>Pharmacotherapy</i> , 2008, 28, 863-874.	2.6	20
61	In vitro pharmacodynamics of novel rifamycin ABI-0043 against <i>Staphylococcus aureus</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 156-160.	3.0	32
62	Attenuated Vancomycin Bactericidal Activity against <i>Staphylococcus aureus</i> hemB Mutants Expressing the Small-Colony-Variant Phenotype. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1533-1537.	3.2	46
63	Drug interactions between proton pump inhibitors and antiretroviral drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2007, 3, 197-207.	3.3	14
64	Phase I and II Study of the Safety, Virologic Effect, and Pharmacokinetics/Pharmacodynamics of Single-Dose 3-(3-(2,3-Dimethylsuccinyl)Betulinic Acid (Bevirimat) against Human Immunodeficiency Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3574-3581.	3.2	164
65	Celecoxib and Mucosal Protection: Translation from an Animal Model to a Phase I Clinical Trial of Celecoxib, Irinotecan, and 5-Fluorouracil. <i>Clinical Cancer Research</i> , 2007, 13, 965-971.	7.0	32
66	Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent. <i>Biochemical Pharmacology</i> , 2007, 73, 1280-1287.	4.4	25
67	Pharmacodynamics of cefprozil against <i>Haemophilus influenzae</i> in an in vitro pharmacodynamic model. <i>Diagnostic Microbiology and Infectious Disease</i> , 2006, 56, 379-386.	1.8	10
68	Development of a Pharmacokinetic and Bayesian Optimal Sampling Model for Individualization of Oral Busulfan in Hematopoietic Stem Cell Transplantation. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 62-66.	2.0	24
69	Drug Interactions between Opioids and Antiretroviral Medications: Interaction between Methadone, LAAM, and Delavirdine. <i>American Journal on Addictions</i> , 2006, 15, 23-34.	1.4	37
70	Sequential administration of irinotecan and cytarabine in the treatment of relapsed and refractory acute myeloid leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 73-83.	2.3	5
71	Inhibition of Atazanavir Oral Absorption by Lansoprazole Gastric Acid Suppression in Healthy Volunteers. <i>Pharmacotherapy</i> , 2006, 26, 341-346.	2.6	72
72	Interactions between Buprenorphine and Antiretrovirals. I. The Nonnucleoside Reverse-Transcriptase Inhibitors Efavirenz and Delavirdine. <i>Clinical Infectious Diseases</i> , 2006, 43, S224-S234.	5.8	81

#	ARTICLE	IF	CITATIONS
73	Interactions between Buprenorphine and Antiretrovirals. II. The Protease Inhibitors Nelfinavir, Lopinavir/Ritonavir, and Ritonavir. <i>Clinical Infectious Diseases</i> , 2006, 43, S235-S246.	5.8	70
74	A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors.. <i>Clinical Cancer Research</i> , 2006, 12, 1237-1244.	7.0	38
75	Gemcitabine and Acute Myocardial Infarction. <i>Angiology</i> , 2006, 57, 367-371.	1.8	24
76	Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2005, 1, 473-485.	3.3	43
77	Application of an In Vitro Infection Model and Simulation for Reevaluation of Fluoroquinolone Breakpoints for Salmonella enterica Serotype Typhi. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 1775-1781.	3.2	48
78	Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 843-854.	4.1	12
79	Pharmacokinetics of Nelfinavir and Efavirenz in Antiretroviral-Naïve, Human Immunodeficiency Virus-Infected Subjects when Administered Alone or in Combination with Nucleoside Analog Reverse Transcriptase Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 3558-3561.	3.2	9
80	Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center. <i>Diagnostic Microbiology and Infectious Disease</i> , 2005, 52, 255-259.	1.8	28
81	Population Pharmacokinetics of Delavirdine and N-Delavirdine in HIV-Infected Individuals. <i>Clinical Pharmacokinetics</i> , 2005, 44, 99-109.	3.5	11
82	Effect of Tenofovir Disoproxil Fumarate on the Pharmacokinetics and Pharmacodynamics of Total, R-, and S-Methadone. <i>Pharmacotherapy</i> , 2004, 24, 970-977.	2.6	17
83	The Influence of St. John's Wort on the Pharmacokinetics and Protein Binding of Imatinib Mesylate. <i>Pharmacotherapy</i> , 2004, 24, 1508-1514.	2.6	119
84	Drug Interactions between Opioids and Antiretroviral Medications: Interaction between Methadone, LAAM, and Nelfinavir. <i>American Journal on Addictions</i> , 2004, 13, 163-180.	1.4	43
85	Induction of imatinib metabolism by hypericum perforatum. <i>Blood</i> , 2004, 104, 1229-1230.	1.4	33
86	Phase I and pharmacokinetic study of anhydrovinblastine every 3 weeks in patients with refractory solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 51, 227-230.	2.3	13
87	Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 51, 376-384.	2.3	15
88	Pharmacokinetics and Pharmacodynamics of Mesna-Mediated Plasma Cysteine Depletion. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 1324-1328.	2.0	15
89	Oxaliplatin in Combination With Protracted-Infusion Fluorouracil and Radiation: Report of a Clinical Trial for Patients With Esophageal Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 2844-2850.	1.6	110
90	Effect of Food on the Pharmacokinetics of (-) and (+) dOTC When Administered as an Oral Racemate. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 658-661.	2.0	1

#	ARTICLE	IF	CITATIONS
91	Clinical Pharmacokinetics of Non-Nucleoside Reverse Transcriptase Inhibitors. <i>Clinical Pharmacokinetics</i> , 2001, 40, 893-905.	3.5	183
92	Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients. <i>Clinical Therapeutics</i> , 2001, 23, 1231-1244.	2.5	60
93	Treating mammalian bite wounds. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2000, 25, 85-99.	1.5	102
94	Safety, Tolerability, and Pharmacokinetics of Single Oral Doses of BCH-10652 in Healthy Adult Males. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 2816-2823.	3.2	4
95	Absolute Bioavailability and Disposition of (âˆ’) and (+) 2â€™-Deoxy- 3â€™-Oxa-4â€™-Thiocytidine (dOTC) following Single Intravenous and Oral Doses of Racemic dOTC in Humans. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 1609-1615.	3.2	12
96	Accuracy of Measured Vancomycin Serum Concentrations in Patients with End-Stage Renal Disease. <i>Annals of Pharmacotherapy</i> , 1999, 33, 1329-1335.	1.9	37
97	Vancomycin-Induced Neutropenia Associated With Fever: Similarities Between Two Immune-Mediated Drug Reactions. <i>Pharmacotherapy</i> , 1999, 19, 240-244.	2.6	30
98	New Modified Fluorescence Polarization Immunoassay Does Not Falsely Elevate Vancomycin Concentrations in Patients With End-Stage Renal Disease. <i>Therapeutic Drug Monitoring</i> , 1998, 20, 231-235.	2.0	25